期刊文献+

金糖宁胶囊治疗2型糖尿病Ⅲ期临床试验观察 被引量:1

下载PDF
导出
摘要 目的在Ⅱ期临床试验安全性、有效性研究的基础上,以拜唐苹片作为对照,通过随机双盲(双模拟)对照试验方法,进一步验证及客观评价金糖宁胶囊治疗2型糖尿病属于湿浊中阻兼血瘀证的临床疗效。方法按新药Ⅲ期临床研究方法,将纳入的480例病例按随机双盲(双模拟)对照试验方法,分为试验组(给予金糖宁胶囊+安慰剂片剂)360例,对照组(拜唐苹片+安慰剂胶囊)120例,符合统计要求的有效病例为试验组338例,对照组112例,给药方法(用餐后即刻口服):试验组服用金糖宁胶囊每次4粒,安慰片剂每次1片,每日3次,共4周;对照组服用拜唐苹片每次1片,安慰胶囊每次4粒,每日3次,共4周,观察治疗4周后两组的治疗效果。结果两组治疗后空腹血糖、餐后2h血糖及糖化血红蛋白水平较治疗前均有显著降低;两组治疗后脘腹胀满、头身困重、倦怠乏力、大便不爽、肢体麻木、肢体疼痛等临床症状均有明显改善,治疗后的中医证候总疗效:试验组总有效率达85.17%,对照组为82.86%。结论金糖宁胶囊用于治疗2型糖尿病属于湿浊中阻兼血瘀证患者能降低患者空腹、餐后2h血糖及糖化血红蛋白水平,对血脂代谢异常有一定的改善作用,并能明显改善患者的主要临床症状。
作者 林进生
出处 《海峡药学》 2008年第8期106-109,共4页 Strait Pharmaceutical Journal
  • 相关文献

参考文献4

二级参考文献10

  • 1Kahn SE,Montgomery B,Howell WM,Ligueros-Saylan M,Hsu C,Devineni D,McLeod J,Horowitz AD.Nateglinide increases first phase insulin secretion and enhances glucose clearance in type 2 diabetes[J].Diabetes,2000; 49 (Suppl 1):A113
  • 2Bruttomesso D,Pianta A,Mari A,Valerio A,Marescotti M-C,Avogaro A,Tiengo A,Del Prato S.Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients[J].Diabetes,1999; 48(1):99-105
  • 3Hu S,Wang S,Fanelli B,Bell PA,Dunning BE,Geisse S,Schmitz R,Boettcher B:Pancreatic β-cell KATP channel activity and membrane binding studies with nateglinide:a comparison with sulfonylureas and repaglinide[J].J Pharmacol Exp Ther,2000;10(293):444-452
  • 4Raskin P,Klaff L,McGill J,South SA,Hollander P,Khutoryansky N,Hale P M.Repaglinide vs.Nateglinide Metformin Combination Study Group.Efficacy and Safety of Combination Therapy Repaglinide plus metformin versus nateglinide plus metformin[J].Diabetes Care,20
  • 5Sato Y,Nishikawa M,Shinkai H,Sukegawa E.Possibility of ideal blood glucose control by a new oral hypoglycemic agent N-[(trans-4-isopropylcyclohexyl)-carbonyl ]-D-phenylalanine (A-4 166),and its stimulatory effect on insulin secretion in animals[J].Diabete
  • 6Definition,diagnosis and classification of diabetes mellitus and its complications report of WHO consultation Part 1:diagnosis and classification of diabetes mellitus[R].World health organization:Geneva,1999
  • 7Kalbag JB,Walter YH,Nedelman JR,McLeod JF.Mealtime glucose regulation with nateglinide in healthy volunteers:comparison with repaglinide and placebo[J].Diabetes Care,2001; 24(1):73-80
  • 8Cohen RM,Ramlo-Halsted BA.How do the new insulin secretagogues compare[J].Diabetes Care.2002; 25(8):1472-1475
  • 9Julio Rosenstock,David R.Hassman,Robert D.Madder,et al.Repaglinide Versus Nateglinide Monotherapy A randomized,multicenter study.Diabetes Care,2004 ; 27:1265-1270
  • 10Karara AH,Dunning BE,McLeod JF.The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects[J].J Clin Pharmacol,1999; 39(11):172-179

共引文献13

同被引文献7

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部